New hope for critically ill patients fighting deadly fungus with damaged livers
NCT ID NCT07337720
Summary
This study is testing the safety and effectiveness of an existing antifungal drug, liposomal amphotericin B, in a specific group of very sick patients. It will include 40 adults in intensive care units across China who have both a severe fungal infection (invasive aspergillosis) and impaired liver function. The goal is to gather real-world evidence to help doctors make better treatment decisions for these high-risk patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPERGILLOSIS INVASIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.